Five Years of Leqembi: The Gap Against Expected Alzheimer's Decline Kept Widening
After five years of continuous lecanemab, 351 people with early Alzheimer's declined 2.05 points less on the CDR-SB than natural-history data, a gap that grew every year. In a low-tau subgroup, 62 percent scored better than at the start.